At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 247 enrolled
Drug / intervention
Glargine U300 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient and Post-Hospital Discharge Management of Medicine and Surgery Patients With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Glargine U300, Glargine U100, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 247 participants across 4 sites.
Detailed Summary
The purpose of this study is to find out if treatment with Glargine U300 when compared to Glargine U100 will result in similar sugar control in patients with Type 2 Diabetes (T2D), who are admitted to the hospital and then transition at home, after discharge from the hospital.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartMay 2017
Primary CompletionMar 2019
TodayJul 2026
First PostedJan 9, 2017
Enrollment StartMay 17, 2017
Primary CompletionMar 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.5 years ago
Interventions
Glargine U300drug
Glargine U300 is a new generation long-acting insulin.
Glargine U100drug
Glargine U100 is a long-acting insulin.
Glulisine Insulindrug
Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.